Solventum Corporation (NYSE:SOLV) Receives Average Rating of “Hold” from Brokerages

Solventum Corporation (NYSE:SOLV) has received an average rating of “Hold” from the fourteen analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $90.8333.

SOLV has been the topic of a number of research analyst reports. UBS Group reiterated a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Stifel Nicolaus upped their price target on shares of Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. BTIG Research upgraded Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Tuesday, December 2nd. Wall Street Zen raised Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Finally, KeyCorp upgraded Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 target price for the company in a research note on Monday.

Solventum Stock Performance

Shares of NYSE SOLV opened at $79.00 on Tuesday. The business’s 50-day simple moving average is $81.71 and its 200-day simple moving average is $75.74. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. Solventum has a 52 week low of $60.70 and a 52 week high of $88.20. The firm has a market cap of $13.70 billion, a price-to-earnings ratio of 9.10, a P/E/G ratio of 7.22 and a beta of 0.34.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The firm had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same quarter in the prior year, the business earned $1.64 earnings per share. The company’s revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, equities research analysts expect that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its board has authorized a stock repurchase plan on Thursday, November 20th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to repurchase up to 7.5% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Hedge Funds Weigh In On Solventum

Several large investors have recently bought and sold shares of SOLV. Hilltop National Bank boosted its holdings in Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum during the third quarter valued at about $25,000. Deseret Mutual Benefit Administrators lifted its stake in shares of Solventum by 78.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after buying an additional 163 shares during the period. JNBA Financial Advisors grew its position in Solventum by 205.4% during the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after buying an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC acquired a new stake in Solventum during the second quarter worth about $28,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.